TriNetX will link genomic and proteomic data with Regeneron through exclusive, secure, licensed access to de-identified health data from roughly 300 million individuals. The deal is designed to support drug discovery and development by improving cohort building and mechanistic research tied to molecular profiles. The collaboration is positioned as a data-integration upgrade rather than a product clinical program, reflecting growing demand for multi-omics real-world evidence to shorten translation cycles. For Regeneron, the partnership adds scale to R&D analytics and strengthens the ability to prioritize targets and evaluate hypotheses across large patient subgroups. For health-data platforms and biotech alike, the key factor is whether proteomics+genomics linkages can be leveraged reliably for actionable discovery and trial-readiness decisions.